News
Neoadjuvant immunotherapy delivers unprecedented pathological response in mismatch repair deficient non-metastatic colon cancers
In patients with non-metastatic colon cancer who have mismatch repair deficient tumours, a short course of neoadjuvant immunotherapy (one cycle ipilimumab and two cycles nivolumab) was highly effective. The NICHE-2 trial, published…
